Jacob Glanville, PhD
Co-founder
Dr. Glanville is a serial biotechnology entrepreneur, computational immune engineer, infectious disease pundit and global medicine access advocate who pioneered deep sequencing and advanced DNA synthesis technologies in antibody library-based discovery. He is founder and CEO of Centivax, previously founder and CEO of Distributed Bio, affiliate professor of USAC, advisory board member of USF biotechnology PSM, responsible for the discovery and engineering of 78 therapeutic antibody programs and 22 antibody libraries across 71 biotechnology companies, including Pfizer, Gilead, Boehringer Ingelheim, Twist, Teva, Novartis, Abbott, Merck, GSK, and 61 others. He has led repertoire analysis efforts of transgenic IgH OMT rat, Trianni mouse, Amgen Xenomouse, Crystal Bioscience transgenic chicken, human, mouse, rabbit, alpaca, llama, pig, chicken, cat, dog, and macaque antibody repertoires. He also conducted analysis contributing to initial discovery of convergent anti-malaria antibodies in Atreca single-cell GSK vaccine data (http://www.centivax.com/jake).
Dr. Glanville obtained his PhD in Computational and Systems Immunology at Stanford University.
Zhongde Wang, PhD
Co-founder, Chief Scientific Officer
Dr. Wang is an expert in animal genetic engineering and epigenetics in animal cloning by somatic cell nuclear transfer (SCNT). Working with the research team that produced the world first transgenic cattle by SCNT, he made great contributions to the development of a novel cattle cloning technique which led to the production of calves that were among the very first cloned cattle (Nat Biotech 2001). Dr. Wang served as an Exc. Director at Hematech Inc. (now SAB Biotherapeutics Inc.) where his research teams successfully established the transchromosomic (Tc) cattle platform for fully-human antibody production. He is now a professor in the Department of Animal, Dairy and Veterinary Sciences at Utah State University.
Dr. Wang obtained his PhD in Molecular and Cellular Biology at University of Massachusetts, Amherst, and conducted his postdoctoral training at MIT/Whitehead Institute.
Michail Sitkovsky, PhD
Co-founder
Dr. Sitkovsky is credited with the landmark discovery of hypoxia-adenosinergic regulation of cells that plays a fundamental role in physiological and pathophysiological mechanisms of disease. This discovery led to the creation of a new industry focus with many start-ups and established global pharmaceutical companies conducting clinical trials of the conceptually novel immunotherapeutic, anti-hypoxia-A2-adenosinergic drugs. Several of the ongoing Phase 2 and Phase 3 trials resulted in promising tumor rejections and life prolongation of cancer patients who were otherwise refractory to all current cancer therapies. One of the important biotechnological spin-offs of this discovery was in biophysical and biochemical reformulation of routine in vitro cell culture in order to better reproduce the in vivo tissue microenvironments and thereby support the physiologically relevant gene expression, epigenetic integrity of immune cells, other somatic cells, stem cells, and healthy embryos for animal cloning.
Dr. Sitkovsky is the Founder and Director of the New England Inflammation and Tissue Protection Institute, and Professor and Eleanor W. Black Chair of immunophysiology and pharmaceutical biotechnology, Northeastern University, Boston. He also was appointed as Presidential Scholar at Dana Farber Cancer Institute, Harvard Medical School.
Jane Kinsel, PhD, MBA
Chief Executive Officer
Most recently Dr. Kinsel managed the business and operations aspects for two biotech start-up companies, including in-licensing intellectual property and drugs from different industry sources, and oversaw the successful acquisition of one of the companies by a large pharmaceutical company. Dr. Kinsel has over 40 years of experience in the pharmaceutical industry, including patents issued for a novel drug delivery system; in federal regulatory oversight at the Food and Drug Administration (FDA), in research funding programs at the National Institutes of Health (NIH); in research infrastructure leadership at a major university; and in coordinating R&D and managing contracts between academia and industry.
Dr. Kinsel earned her PhD in pharmaceutical chemistry from the University of Kansas and her MBA from the Wharton School at the University of Pennsylvania.